Efficacy and Safety of Ginkgo Biloba in Middle-aged Cognitively Intact Adults
NCT02181972, Phase 3, Completed, Boehringer Ingelheim
Trial 10
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
| Field | Value | Source |
|---|---|---|
| Title | Efficacy and Safety of Ginkgo Biloba in Middle-aged Cognitively Intact Adults | ClinicalTrials.gov |
| NCT number | NCT02181972 | ClinicalTrials.gov |
| Status | Completed | ClinicalTrials.gov |
| Phases | Phase 3 | ClinicalTrials.gov |
| Enrollment | 120 participants, actual | ClinicalTrials.gov |
| Lead sponsor | Boehringer Ingelheim | ClinicalTrials.gov |
| Conditions | Healthy | ClinicalTrials.gov |
| Interventions | Gingko biloba, Placebo | ClinicalTrials.gov |
| First posted | 2014-07-08 | ClinicalTrials.gov |
| Last updated | 2014-07-18 | ClinicalTrials.gov |
Registered outcomes 10
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description | Source |
|---|---|---|---|---|
| Primary | Changes from baseline of the cognitive test/CDR (Cognitive Drug Research) factor "Power of Attention) | pre-dose and 2, 4, 6 hours post-dosing at baseline and day 56 | ClinicalTrials.gov | |
| Secondary | Changes from baseline in CDR factors | pre-dose and 2, 4, 6 hours post-dosing at baseline, days 28 and 56 | ClinicalTrials.gov | |
| Secondary | Changes from baseline in Stroop Colour and Word Test | Baseline and day 56 | ClinicalTrials.gov | |
| Secondary | Changes from baseline in the Selective Reminding Test | Baseline and day 56 | ClinicalTrials.gov | |
| Secondary | Changes from baseline in the Trail Making Test (Part A and B) | Baseline and day 56 | ClinicalTrials.gov | |
| Secondary | Number of patients with adverse events | up to 56 days | ClinicalTrials.gov | |
| Secondary | Number of patients with clinically significant changes in vital signs | Baseline, days 28 and 56 | ClinicalTrials.gov | |
| Secondary | Number of patients with abnormal changes in laboratory parameters | Baseline and day 56 | ClinicalTrials.gov | |
| Secondary | Assessment of tolerability by subject on a 4-point scale | Days 28 and 58 | ClinicalTrials.gov | |
| Secondary | Assessment of tolerability by investigator on a 4-point scale | Days 28 and 58 | ClinicalTrials.gov |
Outcomes 0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
| Type | Outcome | Time frame | Population | Units | Measured as | Source |
|---|
Results by group 0
Each measurement the trial posted, group by group, in the words and numbers it posted.
| Outcome | Group | Category | Value | Spread | Units | Source |
|---|
Participant flow 0
How many started, completed or left each group, period by period.
| Period | Milestone | Group | Participants | Units counted | Source |
|---|
Adverse events 0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
| Type | Event | Organ system | Group | Affected | At risk | Events | Source |
|---|
Adverse event totals 0
The totals the trial posted for each group.
| Total | Group | Affected | At risk | Source |
|---|
Papers 0
The papers the trial lists on ClinicalTrials.gov.
| PMID | Listed as | Source |
|---|
Grants 0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
| Project | Title | Principal investigators | Organization | Funder | Fiscal years | Source |
|---|
Trial comparisons 0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
| Comparison | Source |
|---|
Tests 3
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
| Test | Named as | Source |
|---|---|---|
| Selective Reminding Task | Secondary outcome | ConductCognition |
| Stroop Color-Word Test | Secondary outcome | ConductCognition |
| Trail Making Test A | Secondary outcome | ConductCognition |
Source 5
| Field | Value | Source |
|---|---|---|
| Release | trials-2026-11-12-0.4.0 | ClinicalTrials.gov |
| Release manifest SHA-256 | 0f4a8d8c48aee2a7573ae0fa94ecbeab70c1adbe449bbc95c424bc7d3e97b9d4 | ClinicalTrials.gov |
| Registry capture | 2026-11-12 | ClinicalTrials.gov |
| Results copy, AACT | 2026-03-23 | ClinicalTrials.gov |
| NIH clinical studies file | 2026-11-13 | ClinicalTrials.gov |
Release trials-2026-11-12-0.4.0
ClinicalTrials.gov's posted results, through CTTI's AACT: ClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299 ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
ClinicalTrials.gov: none stated ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
NIH RePORTER's clinical studies and project files: Public domain (NIH RePORTER)